SciELO - Scientific Electronic Library Online

 
vol.148 número11Prevalencia de resistencia transmitida a drogas antirretrovirales en pacientes con infección por VIH en Chile (2014-2018)Evaluación de la confiabilidad y validez de constructo de la Escala de Calidad de Vida en Salud SF-12 en población chilena (ENCAVI 2015-6) índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

GUEVARA, David Ladrón de et al. Prognostic value of interim PET/CT in non-hodgkin lymphoma. Rev. méd. Chile [online]. 2020, vol.148, n.11, pp.1558-1567. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872020001101558.

Background:

The prognosis of Non-Hodgkin Lymphoma (NHL) depends on the type of lymphoma, the extension of the disease and the response to therapy.

Aim:

To evaluate the prognostic value of pretreatment and interim PET/CT compared to classic prognosis factors and body composition measurement (sarcopenia, adipopenia) in patients with recently diagnosed NHL.

Material and Methods:

Patients with recently diagnosed NHL who had staging 18F-FDG PET/CT performed between December 2008 and August 2018 were selected. Age, gender, weight, height, B symptoms, laboratory tests, pathology, staging PET/CT findings (Ann Arbor, number of nodal groups and extranodal sites involved, Bulky, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis), Computed Tomography findings (psoas muscle mass index, psoas area, psoas density, subcutaneous fat index (all of them at L3 level), and Deauville score (Lugano Criteria) were recorded. The prognostic value of each of these factors was assessed using Cox multivariable regressions.

Results:

Of 138 NHL studied patients (median 61 y, 15-87 y, 60.4% men), 31 of them died due to the disease. The median follow-up was 39 months (1-115 months). The strongest prognostic factors were: B symptoms (p < 0.01), anemia (p < 0.01), hypoalbuminemia (p: 0.01), sarcopenia (p < 0.01), adipopenia (p < 0.01), number of node groups involved (p < 0.01), MTV (p < 0.01), and a bad response in interim PET/CT (p < 0.01). In a comparative Cox multivariable analysis, interim PET/CT was the independent variable with the highest significance (p < 0.01).

Conclusions:

Early treatment response assessed by interim PET/CT is the strongest prognostic factor in NHL patients.

Palabras clave : Lymphoma, Non-Hodgkin; Multidetector Computed Tomography; Prognosis; Positron-Emission Tomography; Survival.

        · texto en Español     · Español ( pdf )